FGK4.5-CP133單克隆抗體是原始FGK4.5單克隆抗體的重組嵌合型抗體。可變結(jié)構(gòu)域序列與原始FGK4.5克隆號(hào)相同，但是恒定區(qū)序列已經(jīng)從大鼠IgG2a變?yōu)樾∈驣gG2a。FGK4.5-CP133抗體像原始大鼠IgG2a抗體一樣，不包含F(xiàn)c突變。
FGK4.5-CP133單克隆抗體能與小鼠CD40(也稱為Bp50)反應(yīng)。CD40是一種48 kDa的I型跨膜糖蛋白，屬于腫瘤壞死因子受體(TNFR)超家族。CD40廣泛表達(dá)于抗原呈遞細(xì)胞(APCs)，如樹突狀細(xì)胞、B細(xì)胞、巨噬細(xì)胞和單核細(xì)胞，以及非免疫內(nèi)皮細(xì)胞、基底上皮細(xì)胞和一系列腫瘤細(xì)胞上。CD40與其配體CD154結(jié)合后，作為共刺激分子激活B細(xì)胞、樹突狀細(xì)胞、單核細(xì)胞和其他APCs。CD40在B細(xì)胞活化、分化、增殖和免疫球蛋白同種型轉(zhuǎn)換以及樹突狀細(xì)胞成熟中起作用。激動(dòng)性CD40單克隆抗體已被證明能激活A(yù)PCs并促進(jìn)抗腫瘤T細(xì)胞反應(yīng)。FGK4.5單克隆抗體是一種激動(dòng)性抗體，已被證明能激活表達(dá)CD40的APC。FGK4.5單克隆抗體也可用于體外和體內(nèi)抑制CD40/CD154相互作用。
產(chǎn)品詳情：
|
產(chǎn)品名稱 |
RecombiMAb anti-mouse CD40 |
|
產(chǎn)品貨號(hào) |
CP133 |
|
產(chǎn)品規(guī)格 |
1/5/25/50/100mg |
|
反應(yīng)種屬 |
Mouse |
|
克隆號(hào) |
FGK4.5-CP133 |
|
同種型 |
Mouse IgG2a(switched from rat IgG2a) |
|
免疫原 |
Recombinant mouse CD40 fusion protein |
|
實(shí)驗(yàn)應(yīng)用 |
in vivo CD40 activation* |
|
產(chǎn)品形式 |
PBS, pH 7.0,Contains no stabilizers or preservatives |
|
純度 |
>95%, Determined by SDS-PAGE |
|
聚合 |
<5%, Determined by SEC |
|
無菌處理 |
0.2 µm filtration |
|
純化方式 |
Protein G |
|
分子量 |
150 kDa |
|
小鼠病原檢測 |
Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative |
|
保存條件 |
抗體原液保存在4°C，不能冷凍保存。 |
|
推薦同型對(duì)照 |
InVivoPlus mouse IgG2a isotype control, unknown specificity（貨號(hào)BP0085） |
|
推薦抗體稀釋液 |
InVivoPure pH 7.0 Dilution Buffer（貨號(hào)IP0070） |
該產(chǎn)品自上市已被多篇SCI文獻(xiàn)引用，品質(zhì)有保證，以下是部分已發(fā)表的文獻(xiàn)引用：
|
應(yīng)用 |
文章 |
|
體內(nèi)CD40激活 (in vivo CD40 activation) |
1. Bauche, D., et al. (2018). 'LAG3(+) Regulatory T Cells Restrain Interleukin-23- Producing CX3CR1(+) Gut-Resident Macrophages during Group 3 Innate Lymphoid Cell-Driven Colitis' Immunity 49(2): 342-352 e345. 2. Carmi, Y., et al. (2015). 'Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity' Nature 521(7550): 99-104. 3. Conde, P., et al. (2015). 'DC-SIGN(+) Macrophages Control the Induction of Transplantation Tolerance' Immunity 42(6): 1143-1158. 4. Bartkowiak, T., et al. (2015). 'Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine' Proc Natl Acad Sci U S A 112(38): E5290-5299. |
|
體外B細(xì)胞刺激/激活 (in vitro B cell stimulation/activation) |
1. Xu, H., et al. (2015). 'Regulation of bifurcating B cell trajectories by mutual antagonism between transcription factors IRF4 and IRF8' Nat Immunol . 2. Muppidi, J. R., et al. (2014). 'Loss of signalling via Galpha13 in germinal centre B-cell-derived lymphoma' Nature 516(7530): 254-258. |
更多產(chǎn)品詳情請(qǐng)咨詢 BioXCell 中國授權(quán)代理——欣博盛生物
全國服務(wù)熱線: 4006-800-892 郵箱: market@neobioscience.com
深圳: 0755-26755892 北京: 010-88594029
廣州：020-87615159 上海: 021-34613729
代理品牌網(wǎng)站: www.neobioscience.com
自主品牌網(wǎng)站: www.neobioscience.net